Semiquantitative analysis and characterization of physiological biodistribution of 68Ga-DOTA-TATE PET/CT

Clinical Nuclear Medicine

Volumn 37, Issue 11, 2012, Pages 1052-1057

  Kunikowska, Jolanta ^a   Królicki, Leszek ^a   Pawlak, Dariusz ^b   Zerizer, Imene ^c   Mikołajczak, Renata ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NATIONAL CENTRE FOR NUCLEAR RESEARCH   (Poland)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

68Ga DOTA TATE; biodistribution; PET CT; somatostatin receptor

Indexed keywords

68 GALLIUM 1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID 3 TYROSINE OCTREOTATE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ADRENAL GLAND; ADULT; AGED; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FEMUR; FOLLOW UP; HUMAN; HYPOPHYSIS; KIDNEY; LIVER; MAJOR CLINICAL STUDY; MALE; PANCREAS; SALIVARY GLAND; SPLEEN; THYROID GLAND;

FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TISSUE DISTRIBUTION;

EID: 84867855524     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31825b2555     Document Type: Article

References (22)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427. (Pubitemid 37056239)
2. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J. Nucl Med. 2000;41:1704-1713.
3. Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R, et al. 99mTc-EDDA/ HYNIC octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging. 2006;33:1123-1133. (Pubitemid 44488531)
4. Available at: www.idb-holland.com/products/7/15-product-details-gallium- 68-generator.html.
5. BreemanWA, de Jong M, de Blois E, et al. Radiolabelling DOTA-peptides with Ga-68. Eur J Nucl Med Mol Imaging. 2005;32:478-485.
6. Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using Ga-68-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112:2447-2455.
7. Adams S, Baum R, Rink T, et al. Limited value of fluorine-18 fluorodeoxyglucose PET for the imaging of neuroendocrine tumors. Eur J Nucl Med. 1998;25:79-83. (Pubitemid 28107907)
8. Reubi JC, Horisberger U, Kappeler A, et al. Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs. Blood. 1998;92:191-197. (Pubitemid 28303192)
9. Reubi JC,Waser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836-846. (Pubitemid 32662546)
10. Reubi JC, Horisberger U, Studer UE, et al. Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. J Clin Endocrinol Metab. 1993;77:1323-1328. (Pubitemid 23345490)
11. Breder CD, Yamada Y, Yasuda K, et al. Differential expression of somatostatin receptor subtypes in brain. J Neurosci. 1992;12:3920-3934.
12. Singer J, Lincke T, Sabri O, et al. Ga-68-DOTATOC PET detects somatostatin receptors in normal thyroids and various thyroid pathologies. Endocrine Abstracts. 2008;16:OC2.6.
13. Lincke T, Orschekowski G, Singer J, et al. Increased gallium-68 DOTATOC uptake in normal thyroid glands. Horm Metab Res. 2011;43:282-286.
14. Reubi JC, Waser B, Horisberger U, et al. In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood. 1993;82:2143-2151. (Pubitemid 23293998)
15. Reynaert H, Rombouts K, Vandermonde A, et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut. 2004;53:1180-1189. (Pubitemid 38961975)
16. Bates CM, Kegg H, Petrevski C, et al. Expression of somatostatin receptors 3, 4, and 5 in mouse kidney proximal tubules. Kidney Int. 2003;63:53-63. (Pubitemid 35463906)
17. Bates CM, Kegg H, Grady S. Expression of somatostatin receptors 1 and 2 in the adult mouse kidney. Regul Pept. 2004;15:11-20. (Pubitemid 38482097)
18. Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging. 2010; 54:61-67.
19. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518. (Pubitemid 47571404)
20. Boy CH, Heusner T, Poeppel T, et al. Ga-68-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med. 2011;38:1224-1236.
21. Castellucci P, Ucha JP, Fuccio Ch, et al. Incidence of increased Ga-68-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med. 2011;52:886-890.
22. Ibraheem A, Bundschuh RA, Notni J, et al. Focal uptake of Ga-68-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours? Eur J Nucl Med Mol Imaging. 2011;38:2005-2013.